tbuckley/cabot-search huggingface dataset:
The Medical Malpractice System
Authors: Karen L. Posner
Journal: Annals of Internal Medicine (1993)

Letters1 June 1993The Medical Malpractice SystemKaren L. Posner, MD, Frederick W. Cheney, MD, and Robert A. Caplan, MDKaren L. Posner, MDSearch for more papers by this author, Frederick W. Cheney, MDSearch for more papers by this author, and Robert A. Caplan, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-11-199306010-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Taragin and coworkers [1] investigated the medical malpractice tort system through use of closed claims data from the Medical Inter-Insurance Exchange of New Jersey. They presented the conclusion that physician care in malpractice cases is usually defensible and suggested that unjustified payments are probably uncommon. Their findings are generally consistent with the American Society of Anesthesiologists' study of 1004 closed anesthesia malpractice claims [2]. Their study, however, differed from ours and others [3] in one important aspect: In their study the standard of care assessment was not associated with severity of injury. In contrast, we found that ...References1. Taragin MI, Willett LR, Wilczek AP, Trout R, Carson JL. The influence of standard of care and severity of injury on the resolution of medical malpractice claims. Ann Intern Med. 1992; 117:780-4. Google Scholar2. Cheney FW, Posner K, Caplan RA, Ward RJ. Standard of care and anesthesia liability. JAMA. 1989; 261:1599-603. Google Scholar3. Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med. 1991; 324:370-6. Google Scholar4. Caplan RA, Posner KL, Cheney FW. Effect of outcome on physician judgments of appropriateness of care. JAMA. 1991; 265:1957-60. Google Scholar Author, Article, and Disclosure InformationAuthors: Karen L. Posner, MD; Frederick W. Cheney, MD; Robert A. Caplan, MDAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1993Volume 118, Issue 11Page: 908-909KeywordsAnesthesia ePublished: 15 August 2000 Issue Published: 1 June 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Cost-effectiveness of lapatinib plus capecitabine (LAP+C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ+C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the U.K. National Health Service (NHS) perspective.
Authors: O. Sofrygin, T. E. Delea, P. Tappenden, J. Karnon, D. Browning, M. Amonkar, K. Lykopoulos, D. A. Cameron
Journal: Journal of Clinical Oncology (2010)

6037
Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic
Authors: Ankeet S. Bhatt, Alea Moscone, Erin E. McElrath, Anubodh S. Varshney, Brian L. Claggett, Deepak L. Bhatt, James L. Januzzi, Javed Butler, Dale S. Adler, Scott D. Solomon, Muthiah Vaduganathan
Journal: Journal of the American College of Cardiology (2020)
Structural optimization of HPMA copolymer-based dexamethasone prodrug for improved treatment of inflammatory arthritis
Authors: Zhenshan Jia, Gang Zhao, Xin Wei, Dexuan Kong, Yuanyuan Sun, You Zhou, Subodh M. Lele, Edward V. Fehringer, Kevin L. Garvin, Steven R. Goldring, Dong Wang
Journal: Journal of Controlled Release (2020)
Abstract 17086: Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Leads To More Severe Anemia In A Murine Model Of Sickle Cell Disease
Authors: Jessica Venugopal, Jintao Wang, Chiao Guo, Daniel Eitzman
Journal: Circulation (2019)

Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease produced by the liver that targets the low density lipoprotein receptor (LDLR) for degradation. Deficiency of PCSK9...
Inhibition of DNAJ-HSP70 interaction improves strength in muscular dystrophy
Authors: Rocio Bengoechea, Andrew R. Findlay, Ankan K. Bhadra, Hao Shao, Kevin C. Stein, Sara K. Pittman, Jill Daw, Jason E. Gestwicki, Heather L. True, Conrad C. Weihl
Journal: Journal of Clinical Investigation (2020)

Dominant mutations in the HSP70 cochaperone DNAJB6 cause a late-onset muscle disease termed limb-girdle muscular dystrophy type D1 (LGMDD1), which is characterized by protein aggregation and vacuolar myopathology. Disease mutations reside within the G/F domain of DNAJB6, but the molecular mechanisms underlying dysfunction are not well understood. Using yeast, cell culture, and mouse models of LGMDD1, we found that the toxicity associated with disease-associated DNAJB6 required its interaction with HSP70 and that abrogating this interaction genetically or with small molecules was protective. In skeletal muscle, DNAJB6 localizes to the Z-disc with HSP70. Whereas HSP70 normally diffused rapidly between the Z-disc and sarcoplasm, the rate of diffusion of HSP70 in LGMDD1 mouse muscle was diminished, probably because it had an unusual affinity for the Z-disc and mutant DNAJB6. Treating LGMDD1 mice with a small-molecule inhibitor of the DNAJ-HSP70 complex remobilized HSP70, improved strength, and corrected myopathology. These data support a model in which LGMDD1 mutations in DNAJB6 are a gain-of-function disease that is, counterintuitively, mediated via HSP70 binding. Thus, therapeutic approaches targeting HSP70-DNAJB6 may be effective in treating this inherited muscular dystrophy.
The constitutively active EGFR vIII and hyperactive L858R EGFR mutants do not escape Cbl mediated ubiquitination and degradation
Authors: Gareth C. Davies, Phillip E. Ryan, Lambratu Rahman, Maria Zajac-Kaye, Stan Lipkowitz
Journal: Cancer Research (2005)

4306  The overexpression or mutation of tyrosine kinases, such as the Epidermal Growth Factor Receptor (EGFR), can lead to the development of cancer. The Cbl family of ubiquitin ligases (Cbl, Cbl-b, and Cbl-c) targets the activated EGFR for degradation. The evasion of degradation by Cbl proteins provides a mechanism by which EGFR mutants may transform. The most common mutation of the EGFR in glioblastomas is the deletion of exons 2-7 known as the EGFR vIII. This mutant receptor cannot bind its ligand, but is instead constitutively active. Other mutations in the EGFR have been identified in non-small cell lung cancer. These mutations, such as L858R, result in a hyperactive receptor that has increased sensitivity to the EGFR tyrosine kinase inhibitor Gefinitib. Since both the EGFR vIII and the EGFR L858R are transforming, we investigated their ability to avoid Cbl mediated down regulation. Overexpression of all three Cbl proteins resulted in the ubiquitination and lysosomal degradation of the EGFR vIII. This was prevented by inhibition of the EGFR vIII tyrosine kinase by AG 1478. Furthermore, we were able to co-immunoprecipitate Cbl-b and the EGFR vIII. Thus, the Cbl proteins are recruited to the activated EGFR vIII and target it for degradation. As with the wild type (WT) EGFR, the tyrosine kinase binding (TKB) domain and the RING finger of Cbl-b are sufficient for the down regulation of the EGFR vIII. Mutation of the TKB binding site (Y1045F) in the WT EGFR prevents its ubiquitination and down regulation by Cbl proteins. Mutation of this site in the EGFR vIII also prevents its ubiquitination and down regulation by a truncated form of Cbl-b containing only the TKB and RING finger domains. In contrast, full length Cbl-b is still capable of ubiquitinating and down regulating this mutant EGFR vIII, suggesting that the proline rich C-terminus of Cbl-b allows for a second mechanism of interaction with the EGFR vIII. Finally, we found that Cbl-b inhibited the transformation of NIH 3T3 cells by the EGFR vIII. Therefore, Cbl proteins regulate the constitutively active EGFR vIII. Similarly, we found that the hyperactive EGFR L858R is ubiquitinated and degraded by Cbl-b following stimulation by EGF. As a consequence of increased EGF-dependent receptor activation, the EGFR L858R was down regulated faster by Cbl-b than the WT EGFR. In conclusion, the EGFR vIII and the EGFR L858R do not transform by escaping regulation by Cbl proteins. This has important implications in the therapy of tumors expressing these receptors, allowing, for example, the use of antibody based therapies, which enhance or utilize the Cbl dependent down regulation of the EGFR.
Disseminated Bacillus Calmette-Guérin Infection Detected on FDG PET/CT Following Intravesical Bacillus Calmette-Guérin Therapy
Authors: Michael Curley, Hemant Bhardwaj
Journal: Clinical Nuclear Medicine (2020)

Abstract We report the case of a 64-year-old man who presented with back pain, anorexia, and weight loss 9 months following bacillus Calmette-Guérin immunotherapy for high-grade transitional cell carcinoma of the bladder. A FDG PET/CT was performed, which demonstrated osteolysis and intense FDG avidity of the T6/T7 and T8/T9 vertebral endplates. In addition, an aneurysm with FDG-avid soft tissue was present of the distal left common iliac artery. The provisional diagnosis was disseminated bacillus Calmette-Guérin infection, resulting in spondylodiscitis and a mycotic aneurysm. A CT-guided vertebral biopsy confirmed the presence of Mycobacterium tuberculosis DNA on polymerase chain reaction testing.
Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia
Authors: Mark Trinder, Maria L. DeCastro, Hawmid Azizi, Luba Cermakova, Linda M. Jackson, Jiri Frohlich, G.B. John Mancini, Gordon A. Francis, Liam R. Brunham
Journal: Journal of the American College of Cardiology (2020)
Abstract 10150: Direct-to Consumer Cardiology Telemedicine: A Single Large Academic Pediatric Center Experience
Authors: Aaron Phillips, Craig A Sable, Christina Waggaman, Ashraf S Harahsheh
Journal: Circulation (2019)

Introduction: The use of telemedicine in pediatric cardiology has been shown to be time and cost effective. However, there are no reports of using direct to consumer (DTC) telemedicine visits in th...
172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC)
Authors: C.F. Singer, D. Egle, R. Greil, L. Öhler, E. Petru, C. Suppan, M. Marhold, G. Pfeiler, C. Brunner, C. Tinchon, S. Halper, A. Galid, U. Pluschnig, F. Haslbauer, M. Hubalek, A. Redl, J. Flatschacher, M. Hennebelle, B. Mraz, R. Bartsch
Journal: Annals of Oncology (2020)
15300 Maintenance of response through up to 4-years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 trial
Authors: Kristian Reich, Michael Song, Megan Miller, Bruce Randazzo, Paraneedharan Ramachandran, Shu Li, Yin You, Chenglong Han, April W. Armstrong, Peter Foley, Kenneth B. Gordon
Journal: Journal of the American Academy of Dermatology (2020)
Primary Myxedema with Thyrotrophin-Binding Inhibitor Immunoglobulins
Authors: Konishi Junji, Yasuhiro Iida, Kanji Kasagi, Takashi Misaki, Tetsuo Nakashima, Keigo Endo, Toru Mori, Shinichiro Shinpo, Yachiyo Nohara, Nobuo Matsuura, Kanji Torizuka
Journal: Annals of Internal Medicine (2020)

Abstract In a screening of 43 patients with primary myxedema, 9 patients were found to have IgG that inhibits the binding of125I-thyrotrophin to its receptor (thyrotrophin-binding inhibitor immunog...
First-Line Carboplatin Plus Pemetrexed with Pemetrexed Maintenance in HIV+ Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: The Phase II IFCT-1001 CHIVA Trial
Authors: Armelle Lavole, Laurent Greillier, Julien Mazières, Isabelle Monnet, Lize Kiakouama-Maleka, Xavier Quantin, Jean Philippe Spano, Herve Lena, Philippe Fraisse, Henri Janicot, Clarisse Audigier-Valette, Alexandra Langlais, Franck Morin, Alain Makinson, Jacques Cadranel
Journal: European Respiratory Journal (2020)

HIV infection is an exclusion criterion in lung cancer trials. This multicentre phase II trial aimed to assess feasibility, efficacy and safety of first-line carboplatin plus pemetrexed (CaP) followed by pemetrexed (P) maintenance in people living with HIV (PLHIV) with advanced non-squamous non-small cell lung cancer (NS-NSCLC). Four cycles of CaP were followed by P-maintenance therapy in patients with Eastern Cooperative Oncology Group performance status ≤2. The primary objective was a disease control rate (DCR) ≥30% after 12 weeks. Of the 61 PLHIV enrolled, 49 (80%) had a performance status of 0–1, and 19 (31%) had brain metastases. Median CD4 lymphocyte count was 418 cells·µL −1 (range 18–1230), median CD4 lymphocyte nadir was 169.5 cells·µL −1 (1–822); 48 (80%) patients were virologically controlled. Four-cycle inductions were achieved by 38 (62%) patients, and 31 (51%) started P-maintenance (median of 4.1 cycles (range 1–19)). The 12-week DCR was 50.8% (95% CI 38.3–63.4) and partial response rate 21.3%. Median progression-free survival and overall survival were 3.5 (95% CI 2.7–4.4) and 7.6 months (5.7–12.8), respectively. Patients with a performance status of 0–1 had the longest median progression-free survival (4.3 months, 95% CI 3.1–5.2) and overall survival (11.9 months, 95% CI 6.4–14.3). During induction, CaP doublet was well tolerated apart from grade 3–4 haematological toxicities (neutropenia 53.8%; thrombocytopenia 35.0%; anaemia 30.0%). Two fatal treatment-related sepses were reported. No opportunistic infections were experienced. In PLHIV with advanced NS-NSCLC, first-line four-cycle CaP induction followed by P-maintenance was effective and reasonably well-tolerated. Further studies should evaluate combination strategies of CaP with immunotherapy in PLHIV.
Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer
Authors: Maria Paula Roberti, Satoru Yonekura, Connie P. M. Duong, Marion Picard, Gladys Ferrere, Maryam Tidjani Alou, Conrad Rauber, Valerio Iebba, Christian H. K. Lehmann, Lukas Amon, Diana Dudziak, Lisa Derosa, Bertrand Routy, Caroline Flament, Corentin Richard, Romain Daillère, Aurélie Fluckiger, Isabelle Van Seuningen, Mathias Chamaillard, Audrey Vincent, Stephanie Kourula, Paule Opolon, Pierre Ly, Eugénie Pizzato, Sonia Becharef, Juliette Paillet, Christophe Klein, Florence Marliot, Filippo Pietrantonio, Stéphane Benoist, Jean-Yves Scoazec, Peggy Dartigues, Antoine Hollebecque, David Malka, Franck Pagès, Jérôme Galon, Ivo Gomperts Boneca, Patricia Lepage, Bernard Ryffel, Didier Raoult, Alexander Eggermont, Tom Vanden Berghe, François Ghiringhelli, Peter Vandenabeele, Guido Kroemer, Laurence Zitvogel
Journal: Nature Medicine (2020)
Clinical decision making: from theory to practice. Rationing resources while improving quality. How to get more for less
Authors: D M Eddy
Journal: JAMA (1994)

MY LAST article concluded with a very unpleasant idea— that rationing services, refusing to cover a service from shared resources, is inevitable.<sup>1</sup>Although no one knows the correct proportion of the gross domestic product (GDP) that health care should consume, it is clear that one way or another, sooner or later, the growth must be stabilized. Ideally, we would like to find all the required savings in administrative and operational inefficiencies, without having to touch the content of care. Unfortunately, an analysis of the increases in health care costs over the last 30 years indicates that about two thirds of the excess increase—the portion of the increase that exceeds the general inflation rate and population growth— is caused by increases in the "volume and intensity of services." The other third is caused by medical price inflation that exceeds general price inflation. These two forces exist in large part because
Oxido-Reductive Regulation of Human Vascular Remodeling by the Orphan Receptor Tyrosine Kinase Ros1
Authors: Z A Ali, Perez Vdj., K Yuan, M Orcholski, S Pan, W Qi, G Chopra, C Adams, Y Kojima, N J Leeper, K Zaleta-Rivera, K Kato, Y Yamada, M Oguri, S L Hazen, J W Jukema, S K Ganesh, E G Nebel, K Channon, M B Leon, A Charest, T Quertermous, E A Ashley
Journal: Circulation (2014)
Novel and reliable DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis
Authors: Alen Zabotti, Garifallia Sakellariou, Ilaria Tinazzi, Luca Idolazzi, Alberto Batticciotto, Marco Canzoni, Greta Carrara, Orazio De Lucia, Fabiana Figus, Nicolò Girolimetto, Pierluigi Macchioni, Rebecca McConnell, Niccolò Possemato, Annamaria Iagnocco
Journal: Annals of the Rheumatic Diseases (2020)

Objectives Dactylitis is one of the most typical features of psoriatic arthritis (PsA), with a high lifetime prevalence and inclusion in PsA clinical indices. Musculoskeletal ultrasonography (Msk-US) can readily detect inflammatory involvement of finger anatomical structures particular to dactylitis and monitor therapeutic effects. In this study, we aim to identify the characteristic lesions in PsA dactylitis of the hands, assess the reliability of Msk-US in scoring those lesions and develop a DACTylitis glObal Sonographic (DACTOS) score. Methods After a systematic literature review on the use of Msk-US in PsA dactylitis, 12 rheumatologists participated in a three-round Delphi procedure and consensus meeting to agree on the sonographic elementary lesions characterising dactylitis and on the composition of a global sonographic score. Then, a web-based and a patient-based intra-rater and inter-rater reliability exercise was performed to assess those lesions included in the score. Results DACTOS score was obtained by summing the scores of each lesion selected in the Delphi survey: subcutaneous soft tissue oedema, flexor tenosynovitis, peritendon extensor inflammation and synovitis. The DACTOS score ranges from 0 to 25. In the reliability exercises, we obtained moderate-to-excellent agreement for the sonographic lesions included in the score. Conclusions The novel DACTOS score is a reliable measure to interpret the multiple characteristic sonographic features of dactylitis. The DACTOS score provides a useful global analysis of dactylitis of the hand and can represent a support to clinical diagnosis as well as a useful tool for the management and research in patients with PsA with dactylitis.
The Cell Biology of Human Aging
Authors: Leonard Hayflick
Journal: New England Journal of Medicine (1976)

Of all the conflicting views on the causes of biologic aging, there is little disagreement with the axiom that, after reaching sexual maturity, individual members of a species accumulate physiologic decrements that lead to an increase in their likelihood of dying. In fact, for man the actuarial data, first analyzed by the English actuary Gompertz in 1825, reveal that the force of mortality doubles every seven years beyond the age of 30 — that is, after maturity, the rate and probability of dying are exponential with increasing age. The decrements in a variety of human physiologic functions, although subject to . . .
18F-FDG PET/CT in Sporadic Creutzfeldt-Jakob Disease
Authors: Ghali Zizi, Henri Berger, Paul Lalire, Sébastien Dejust, David Morland
Journal: Clinical Nuclear Medicine (2020)

Abstract We report the case of a 64-year-old man referred for optic ataxia, constructional apraxia, and spatial orientation disorders evolving for 2 months. Benson syndrome (posterior cortical atrophy) was initially suspected. Brain 18 F-FDG PET/CT depicted an asymmetric decreased uptake pattern consistent with Creutzfeldt-Jakob disease. 14-3-3 proteins were detected in the cerebrospinal fluid. Clinical evolution was quickly unfavorable. The patient died 1 month after the PET/CT, and Creutzfeldt-Jakob disease was confirmed on postmortem examination of brain tissue.
Police Detainment of a Patient Following Treatment With Radioactive Iodine
Authors: Christoph Buettner, Martin I. Surks
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of erector spinae plane block on postoperative pain and side-effects in adult patients underwent surgery: A systematic review and meta-analysis of randomized controlled trials
Authors: Qiang Cai, Guo-qing Liu, Lin-sheng Huang, Zi-xuan Yang, Mei-ling Gao, Ren Jing, Zhen Liu, Ling-hui Pan
Journal: International Journal of Surgery (2020)
Solid phase micro-extraction (SPME) of volatile molecules in body fluids as a diagnostic measure for pancreatic cancer
Authors: Frederic Zenhausern, Stephen P. Rogers, Haiyong Han, Ruben Munoz, Daniel von Hoff
Journal: Cancer Research (2008)

4471  Pancreatic cancer is the fourth leading cause of death from cancer in the United States. More than 33,000 people nation wide will die from pancreatic cancer this year. The overall five-year survival is less than 4%. This dismal picture of pancreatic cancer is mainly due to the lack of early diagnosis and effective treatment for patients with advanced disease. The best way to increase the survival rate is early detection of the disease by screening for “markers”. Analytical methodology using solid phase micro-extraction (SPME) in combination with gas chromatography and mass spectrometry (GC/MS) will be described to find new prognostic and diagnostic volatile organic compounds related to pancreatic cancer. By comparing the GC/MS profiles of normal healthy SPME samples to the profiles resulting from SPME samples of pancreatic cancer cells or patients with pancreatic cancer, a quantifiable differentiation in the component profiles could become apparent.  We will report some preliminary data resulting from the SPME and GC/MS analysis of pancreatic serum samples obtained on 12 samples, 6 of which were obtained from patients with pancreatic cancer and the remain 6 from healthy volunteers. The volatile compound profiles of this limited sample set of serum samples were very similar in chromatographic appearance (as to be expected for the variation in human population) and showed, quantitative subtleties, even in this well known A vs. B biological sample set. However, normalized peak area ratios of peak 2 to peak 7 and peak 6 to peak 7 suggested a differentiation between the normal vs. pancreatic cancer serum samples. Preliminary identifications for the peaks were cyclopentanone (2), m-xylene (6), and cyclohexanone (7). Data analyses for identifying target metabolic pathways and further experimental development will be reported.
46P Tumour infiltrating lymphocytes in breast cancer: High levels of CD3, CD8 cells and Immunoscore® are associated with pathological CR in patients receiving neo-adjuvant chemotherapy
Authors: B.L. Rapoport, J. Galon, S. Nayler, B. Mlecnik, A. Fugon, C.A. Benn, M. Martel, T. Cronje, T. Smit, F. Moosa, L. Jooste, R. Anderson
Journal: Annals of Oncology (2020)